{"filing":{"accession_number":"0001213900-26-096233","cik":"0001631487","ticker":"CLGN","company_name":"CollPlant Biotechnologies Ltd","form":"6-K","filing_date":"2026-09-01","report_date":"2026-09-01","primary_document":"ea0304205-6k_collplant.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1631487/000121390026096233/ea0304205-6k_collplant.htm"},"events":[{"id":31011,"run_id":28440,"accession_number":"0001213900-26-096233","anchor_item_number":"EX-99.1","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"summary":"CollPlant announces a one-for-ten reverse share split explicitly \"being implemented as part of the Company's strategic plan to regain compliance with the Nasdaq minimum bid price requirement for continued listing.\" This is a direct response to delisting risk — the company is taking corrective action to avoid loss of listing status. While the reverse split itself is a capital structure event, the disclosure's material substance is the underlying delisting threat and the company's remedial measure.","company_name":"CollPlant Biotechnologies Ltd","ticker":"CLGN","filing_date":"2026-09-01","form":"6-K","submitted_at":null,"items":[{"id":33780,"accession_number":"0001213900-26-096233","item_number":"EX-99.1","item_title":"ea030420501ex99-1.htm","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"reasoning":"CollPlant announces a one-for-ten reverse share split explicitly \"being implemented as part of the Company's strategic plan to regain compliance with the Nasdaq minimum bid price requirement for continued listing.\" This is a direct response to delisting risk — the company is taking corrective action to avoid loss of listing status. While the reverse split itself is a capital structure event, the disclosure's material substance is the underlying delisting threat and the company's remedial measure.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-01T20:32:04.228450+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":33780,"accession_number":"0001213900-26-096233","item_number":"EX-99.1","item_title":"ea030420501ex99-1.htm","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"reasoning":"CollPlant announces a one-for-ten reverse share split explicitly \"being implemented as part of the Company's strategic plan to regain compliance with the Nasdaq minimum bid price requirement for continued listing.\" This is a direct response to delisting risk — the company is taking corrective action to avoid loss of listing status. While the reverse split itself is a capital structure event, the disclosure's material substance is the underlying delisting threat and the company's remedial measure.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-01T20:32:04.228450+00:00","company_name":"CollPlant Biotechnologies Ltd","ticker":"CLGN","filing_date":"2026-09-01"}]}